6 completed. 4 Phase 2, 2 Phase 1.
By phase and status
Follow E 5555: new trials by email Literature Review of E 5555 trials Research Report on E 5555
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy Subjects
E5555 100 mg and diltiazem, E5555 300 mg and diltiazem - Healthy Subjects | Phase 1 | Completed | Eisai Inc. | 24 | 2010-10-01 | 2014-07-11 |
Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity
E5555 - Healthy Subjects | Phase 1 | Completed | Eisai Inc. | 104 | 2010-10-01 | 2014-07-11 |
A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome
E5555, Placebo - Acute Coronary Syndrome | Phase 2 | Completed | Eisai Co., Ltd. | 240 | 2007-11-01 | 2013-05-13 |
A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease
E5555 50 mg, E5555 100 mg, E5555 200 mg - Coronary Artery Disease | Phase 2 | Completed | Eisai Co., Ltd. | 240 | 2007-10-01 | 2013-05-13 |
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome
E5555, Placebo - Acute Coronary Syndrome | Phase 2 | Completed | Eisai Inc. | 600 | 2007-10-01 | 2016-02-04 |
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease
E5555, Placebo - Coronary Artery Disease | Phase 2 | Completed | Eisai Inc. | 720 | 2007-09-01 | 2016-12-05 |
Conditions studied
Acute Coronary Syndrome (2) · Coronary Artery Disease (2) · Coronary Stenosis (1) · Coronary Thrombosis (1)
Sponsors
Eisai Inc. (4) · Eisai Co., Ltd. (2)
Countries
United States (3) · Japan (2) · Netherlands (1) · United Kingdom (1)
Top investigators
Masaru Takeuchi (2) · Chukwuemeka Okereke (1) · Dr. Bhaskar Rege (1) · John Riefler, MD (1) · Rafal Ziecina, MD (1)
Results publications
PMID 21502571, PMID 21502577
NIH funding
2005 (1)